India is on the verge of authorizing its first widely available dengue vaccine, following a critical recommendation from an expert panel associated with the Central Drugs Standard Control Organisation (CDSCO). This decision comes as the country experiences an increase in dengue cases, linked to climate change, emphasizing the need for preventive measures beyond traditional vector control. The Subject Expert Committee (SEC) reviewed a wealth of clinical data from both global and Indian studies and concluded that the vaccine has an acceptable safety profile and proven efficacy, thus facilitating its path toward regulatory approval.

Vaccine Target Population and Impact

If granted approval by the national drug regulator, the vaccine is set to be administered to individuals aged between 4 and 60 years. This development represents a notable shift in India’s approach to dengue management, which has primarily relied on mosquito control methods and supportive care. Currently, this vaccine is the sole one authorized to combat dengue worldwide, having already received approval in 41 countries, including those in the European Union, the United Kingdom, and various dengue-endemic regions in Southeast Asia.

Efficacy and Global Recognition

The vaccine, known as QDenga or TK-003, has shown approximately 64 percent efficacy in individuals previously exposed to dengue and around 54 percent efficacy in those who have never contracted the virus. It has also been pre-qualified by the World Health Organisation (WHO), a significant endorsement that supports its integration into public immunization initiatives. The vaccination schedule consists of two doses administered three months apart, aligning with WHO recommendations that endorse its use for children aged 6 to 16 years in areas of high transmission.

Dengue as a Global Health Concern

Dengue was identified as one of the top ten global health threats by the WHO in 2019. The disease presents various symptoms, including high fever, headaches, vomiting, and joint pain, often accompanied by rashes and itching. In severe cases, dengue can lead to life-threatening complications such as dengue hemorrhagic fever, characterized by bleeding and dangerously low platelet levels. Transmission primarily occurs via Aedes aegypti mosquitoes, with Aedes albopictus also being a contributing factor. Any of the four dengue virus serotypes can cause the illness.

Regulatory Approval and Study Findings

Since its launch, approximately 24.4 million doses of the vaccine have been distributed globally, with post-marketing surveillance findings indicating no significant safety issues beyond those observed in clinical trials. The SEC’s recommendation draws from robust evidence from multiple clinical development phases, including data from a large Phase III trial that involved over 20,000 participants across eight countries, among them Brazil, Thailand, and Sri Lanka. The vaccine has been studied in more than 28,000 individuals through 17 clinical trials in both dengue-endemic and non-endemic regions.

Future Directions and Research Requirements

In India, a Phase III assessment involving 480 participants aged 4 to 60 evaluated its safety and immune response. The findings indicated that the vaccine is “well tolerated, safe, and immunogenic” across different age brackets. However, the committee has stipulated that Takeda must conduct follow-up safety and effectiveness studies within six months of the vaccine’s introduction. This aligns with WHO recommendations that support routine dengue vaccinations in high transmission settings without requiring prior screenings, making it operationally advantageous in countries like India.

Challenges in Dengue Control

The urgency for this vaccine is highlighted by the growing burden of dengue in India. The country recorded over 111,000 cases last year, resulting in 95 fatalities, although many cases are likely unreported. India often ranks among the top 30 countries with the highest dengue burden, particularly affecting children, who are at greater risk of severe disease and hospitalization. Virologists caution that the complexity of dengue arises from its four serotypes, with prior infection providing immunity only to that strain, making a tetravalent vaccine essential.

Emerging Alternatives and Holistic Approaches

While Takeda’s vaccine is poised to become the first approved dengue vaccine in India, it may soon face competition. An indigenous vaccine named DengiAll, developed by Panacea Biotec in conjunction with the Indian Council of Medical Research (ICMR), is undergoing Phase III trials and aims for a launch around 2027. Public health experts emphasize that vaccines alone will not suffice; effective dengue management will still rely on integrated strategies, including mosquito control, community education, and early clinical intervention.

Long or Short, get news the way you like. No ads. No redirections. Download Newspin and Stay Alert, The CSR Journal Mobile app, for fast, crisp, clean updates!

App Store –  https://apps.apple.com/in/app/newspin/id6746449540 

Google Play Store – https://play.google.com/store/apps/details?id=com.inventifweb.newspin&pcampaignid=web_share